Aditxt Inc. Subsidiary Pearsanta Advances in DoD-Funded Ovarian Cancer Diagnostic Study
Aditxt Inc.'s subsidiary Pearsanta moves forward in a Department of Defense-funded study for early ovarian cancer detection, highlighting the potential impact on women's health diagnostics.
Aditxt Inc. (NASDAQ: ADTX) has announced a significant step forward for its subsidiary Pearsanta, Inc., which has been invited to submit a full proposal for the U.S. Department of Defense’s OCRP Pilot Award. This opportunity focuses on the development of Pearsanta’s Mitomic(R) Ovarian Test (MOT(TM)), a pioneering blood-based diagnostic designed for the early detection of ovarian cancer. The pre-proposal submitted by Pearsanta received positive feedback for its scientific merit and innovation, marking a critical milestone in the advancement of ovarian cancer diagnostics.
If successful, the grant could provide up to $350,000 over two years to support the validation of the MOT(TM) through a multi-center clinical study and prepare for its commercial launch as a laboratory-developed test. This development is not only a testament to the potential of Pearsanta’s diagnostic technology but also underscores the importance of early detection in improving outcomes for ovarian cancer patients. The initiative represents a collaborative effort between the public and private sectors to address a pressing health challenge, with implications for the future of women's health diagnostics and care.
For further details on this announcement, visit https://ibn.fm/lep5n.